Sage’s quick flip into PhIII crashes as lead drug fails badly for rare type of seizures
After building intense interest in its lead drug for super-refractory status epilepticus with data from tiny studies, Sage Therapeutics $SAGE says the drug failed badly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
